

**REMARKS**

Reconsideration of this application is respectfully requested. Claims 5, 26 and 27 have been amended as discussed below. Claims 1-12 and 15-31 are pending. Because claims 1-4, 6-12, 15-25, and 28-31 have been allowed, only claims 5, 26, and 27 are at issue.

**Indefiniteness Rejections**

Claims 5 and 26 have been rejected under 35 U.S.C. §112, second paragraph, as indefinite. The Examiner contends that the phrase "human growth hormones recombinant growth hormones (rhGH)" in claim 5 is unclear.

A comma has been inserted between the terms "human growth hormones" and "recombinant human growth hormones (rhGH)" in claim 5 to clarify that the active agent can be a human growth hormone or a recombinant human growth hormone.

---

The Examiner also contends that the phrase "the dosage unit form comprising a dosing vehicle comprising a tablet, a capsule, a powder, or a liquid" in claim 26 is unclear since the specification states that the dosage unit form can be in the form of a tablet, a capsule, a powder, or a liquid. Claim 26 has been amended to state that the dosage unit form is in the form of a tablet, a capsule, a powder, or a liquid.

For the foregoing reasons, applicants respectfully request withdrawal of this rejection.


**Objection to Claim 27**

Claim 27 has been objected to due to a misspelled word. Claim 27 has been amended to replace the word "or" with "of." Applicants respectfully request withdrawal of this objection.

In view of the above amendments and arguments, the pending claims in this application are believed to be in condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

Dated: April 2, 2007

Respectfully submitted,

By 

Jay P. Lesser

Registration No. 41,151  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant